Our results suggest that CG0009 is an efficient cytotoxic agent, which is sufficient for low-dose monotherapy, and p53 activation after GSK3 inhibition plays an important role in CG0009-induced breast cancer cell death. The gene discussed is TP53; the disease is breast carcinoma.